Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

IDEXX Laboratories, Inc. provides diagnostic, detection, and information systems for veterinary, food, and water testing applications. The Company also operates an international network of veterinary reference laboratories. IDEXX offers its products to customers worldwide.
Website: idexx.com



Growth: Pretty weak revenue growth rate 8.8%, there is slowdown compared to average historical growth rates 10.9%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of +4.3%

Profitability: LTM EBITDA margin is positive, +33.1%. On average the margin is decreasing unsteadily. Gross margin is high, +58.4%. In the last quarter the company beat the estimated EPS, +5.4%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.07 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 0.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 46.7% higher than minimum and 32.5% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.6x by EV / Sales multiple , the company can be 67.5% overvalued

Insiders: For the last 3 months insiders sold company shares on $30.2 mln (-0.064% of cap.)

Key Financials (Download financials)

Ticker: IDXX
Share price, USD:  (-0.3%)476.35
year average price 500.12  


year start price 495.65 2023-04-21

min close price 391.37 2023-10-27

max close price 576.87 2024-03-01

current price 476.35 2024-04-20
Common stocks: 83 088 000

Dividend Yield:  0.0%
EV / LTM EBITDA: 33.8x
EV / EBITDA annualized: 36.3x
Last revenue growth (y/y):  8.8%
Last growth of EBITDA (y/y):  7.2%
Historical revenue growth:  10.9%
Historical growth of EBITDA:  16.7%
EV / Sales: 11.2x
Margin (EBITDA LTM / Revenue): 33.1%
Fundamental value created in LTM:
Market Cap ($m): 39 579
Net Debt ($m): 1 348
EV (Enterprise Value): 40 927
Price to Book: 26.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-19Zacks Investment Research

What Lies Ahead of IDEXX Laboratories (IDXX) in Q1 Earnings?

2024-04-18Zacks Investment Research

TMO vs. IDXX: Which Stock Is the Better Value Option?

2024-04-09Zacks Investment Research

Idexx Laboratories (IDXX) Beats Stock Market Upswing: What Investors Need to Know

2024-04-09Zacks Investment Research

All You Need to Know About Idexx (IDXX) Rating Upgrade to Buy

2024-04-05Zacks Investment Research

Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report?

2024-04-02Zacks Investment Research

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

2024-02-15Zacks Investment Research

Here's Why You Should Retain IDEXX (IDXX) Stock for Now

2024-02-08Zacks Investment Research

IDEXX's (IDXX) Global Growth Continues, Currency Woes Persist

2024-02-05Seeking Alpha

IDEXX Laboratories, Inc. (IDXX) Q4 2023 Earnings Call Transcript

2024-02-05Zacks Investment Research

IDEXX (IDXX) Q4 Earnings Surpass Estimates, Margins Fall
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IDXX IDXX IDXX IDXX IDXX IDXX
reportedCurrency USD USD USD USD USD USD
cik 874 716 874 716 874 716 874 716 874 716 874 716
fillingDate 2024-02-22 2023-11-01 2023-08-01 2023-05-02 2023-02-16 2022-11-01
acceptedDate 2024-02-22 16:17:19 2023-11-01 16:20:22 2023-08-01 16:08:19 2023-05-02 16:02:30 2023-02-16 17:08:02 2022-11-01 16:33:30
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 902M 916M 944M 900M 829M 842M
costOfRevenue 375M 368M 371M 357M 344M 335M
grossProfit 526M 548M 573M 543M 485M 507M
grossProfitRatio 0.584 0.599 0.607 0.603 0.585 0.602
researchAndDevelopmentExpenses 52M 48M 47M 45M 43M 48M
generalAndAdministrativeExpenses 87M 89M 90M 70M 83M 84M
sellingAndMarketingExpenses 142M 136M 141M 148M 132M 130M
sellingGeneralAndAdministrativeExpenses 229M 225M 230M 218M 215M 214M
otherExpenses 0 0 0 0 0 0
operatingExpenses 281M 273M 277M 263M 258M 262M
costAndExpenses 656M 640M 647M 620M 602M 597M
interestIncome 4M 1M 327 000 416 000 235 000 353 000
interestExpense -6M -7M 10M 13M 13M 11M
depreciationAndAmortization 30M 29M 28M 28M 29M 29M
ebitda 245M 275M 296M 280M 227M 274M
ebitdaratio 0.272 0.301 0.314 0.311 0.273 0.325
operatingIncome 245M 275M 296M 280M 227M 245M
operatingIncomeRatio 0.272 0.301 0.314 0.311 0.273 0.291
totalOtherIncomeExpensesNet -6M -7M -10M -13M -13M -11M
incomeBeforeTax 240M 268M 286M 268M 213M 234M
incomeBeforeTaxRatio 0.266 0.293 0.303 0.297 0.257 0.278
incomeTaxExpense 45M 56M 62M 54M 41M 53M
netIncome 195M 212M 224M 214M 172M 181M
netIncomeRatio 0.216 0.232 0.238 0.238 0.208 0.215
eps 2.340 2.550 2.700 2.580 2.080 2.170
epsdiluted 2.320 2.530 2.670 2.550 2.050 2.150
weightedAverageShsOut 83M 83M 83M 83M 83M 83M
weightedAverageShsOutDil 84M 84M 84M 84M 84M 84M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IDXX IDXX IDXX IDXX IDXX IDXX
reportedCurrency USD USD USD USD USD USD
cik 874 716 874 716 874 716 874 716 874 716 874 716
fillingDate 2024-02-22 2023-11-01 2023-08-01 2023-05-02 2023-02-16 2022-11-01
acceptedDate 2024-02-22 16:17:19 2023-11-01 16:20:22 2023-08-01 16:08:19 2023-05-02 16:02:30 2023-02-16 17:08:02 2022-11-01 16:33:30
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 454M 332M 133M 111M 113M 99M
shortTermInvestments 0 0 0 0 0 0
cashAndShortTermInvestments 454M 332M 133M 111M 113M 99M
netReceivables 457M 453M 462M 446M 401M 475M
inventory 380M 394M 395M 391M 368M 355M
otherCurrentAssets 204M 206M 189M 201M 220M 129M
totalCurrentAssets 1 495M 1 384M 1 179M 1 149M 1 101M 1 059M
propertyPlantEquipmentNet 702M 687M 683M 665M 649M 723M
goodwill 366M 362M 364M 363M 362M 355M
intangibleAssets 85M 87M 91M 94M 98M 100M
goodwillAndIntangibleAssets 450M 449M 455M 457M 459M 455M
longTermInvestments 56M -459M -461M 54M 56M 52M
taxAssets 107M 11M 6M 6M 55M 52M
otherNonCurrentAssets 448M 1 015M 1 009M 476M 426M 300M
totalNonCurrentAssets 1 765M 1 702M 1 692M 1 659M 1 645M 1 581M
otherAssets 0 0 0 0 0 0
totalAssets 3 260M 3 086M 2 871M 2 808M 2 747M 2 640M
accountPayables 111M 113M 108M 118M 110M 110M
shortTermDebt 325M 400M 339M 506M 654M 652M
taxPayables 87M 50M 82M 73M 49M 35M
deferredRevenue 37M 37M 38M 38M 38M 41M
otherCurrentLiabilities 479M 420M 399M 404M 434M 387M
totalCurrentLiabilities 952M 970M 884M 1 066M 1 236M 1 190M
longTermDebt 623M 619M 697M 696M 694M 854M
deferredRevenueNonCurrent 29M 28M 29M 30M 31M 35M
deferredTaxLiabilitiesNonCurrent 7M -28M -29M 6M 8M 14M
otherNonCurrentLiabilities 165M 200M 196M 169M 169M 171M
totalNonCurrentLiabilities 824M 819M 893M 902M 902M 974M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 119M 101M 97M 98M 122M 112M
totalLiabilities 1 775M 1 789M 1 777M 1 967M 2 138M 2 164M
preferredStock 0 0 0 0 0 0
commonStock 11M 11M 11M 11M 11M 11M
retainedEarnings 4 445M 4 250M 4 038M 3 814M 3 600M 3 427M
accumulatedOtherComprehensiveIncomeLoss -71M -75M -74M -77M -78M -81M
othertotalStockholdersEquity -2 900M -2 888M -2 881M -2 907M -2 924M -2 881M
totalStockholdersEquity 1 485M 1 297M 1 094M 841M 609M 476M
totalEquity 1 485M 1 297M 1 094M 841M 609M 476M
totalLiabilitiesAndStockholdersEquity 3 260M 3 086M 2 871M 2 808M 2 747M 2 640M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 3 260M 3 086M 2 871M 2 808M 2 747M 2 640M
totalInvestments 56M -459M -461M 54M 56M 52M
totalDebt 948M 1 019M 1 036M 1 203M 1 348M 1 506M
netDebt 494M 687M 903M 1 091M 1 236M 1 407M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IDXX IDXX IDXX IDXX IDXX IDXX
reportedCurrency USD USD USD USD USD USD
cik 874 716 874 716 874 716 874 716 874 716 874 716
fillingDate 2024-02-22 2023-11-01 2023-08-01 2023-05-02 2023-02-16 2022-11-01
acceptedDate 2024-02-22 16:17:19 2023-11-01 16:20:22 2023-08-01 16:08:19 2023-05-02 16:02:30 2023-02-16 17:08:02 2022-11-01 16:33:30
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome 195M 212M 224M 214M 172M 181M
depreciationAndAmortization 30M 29M 28M 28M 29M 29M
deferredIncomeTax -34M -2M -9M -4M 2M -13M
stockBasedCompensation 15M 15M 15M 14M 13M 13M
changeInWorkingCapital 42M 16M -60M -71M -44M -23M
accountsReceivables 686 000 7M -17M -44M -6M 19M
inventory 3M 7M -15M -24M -22M -50M
accountsPayables 6M -3M -7M 3M 7M 3M
otherWorkingCapital 32M 5M -20M 65M -23M 6M
otherNonCashItems 2M 2M 2M 2M 1M 3M
netCashProvidedByOperatingActivities 250M 272M 200M 184M 173M 189M
investmentsInPropertyPlantAndEquipment -33M -34M -27M -40M -39M -38M
acquisitionsNet 0 0 0 0 -10M -12M
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 2M 0 0 0 0 0
otherInvestingActivites -1.000 6M 0 0 0 0
netCashUsedForInvestingActivites -30M -28M -27M -40M -49M -49M
debtRepayment -75M -14M 0 0 -431M 0
commonStockIssued 11M 13M 0 13M 36M 0
commonStockRepurchased -37M -35M -10M 0 -74M -173M
dividendsPaid 0 -1M 0 0 0 0
otherFinancingActivites -1M -5M -141M -159M 352M 24M
netCashUsedProvidedByFinancingActivities -102M -43M -151M -146M -117M -149M
effectOfForexChangesOnCash 5M -3M -340 000 501 000 6M -6M
netChangeInCash 122M 199M 21M -1M 13M -15M
cashAtEndOfPeriod 454M 332M 133M 111M 113M 99M
cashAtBeginningOfPeriod 332M 133M 111M 113M 99M 114M
operatingCashFlow 250M 272M 200M 184M 173M 189M
capitalExpenditure -33M -34M -27M -40M -39M -38M
freeCashFlow 217M 238M 173M 144M 134M 151M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-05 ET (fiscal 2023 q4)
2023 q3
2023-11-01 ET (fiscal 2023 q3)
2023 q2
2023-08-01 ET (fiscal 2023 q2)
2023 q1
2023-05-02 ET (fiscal 2023 q1)
2022 q4
2023-02-06 ET (fiscal 2022 q4)
2022 q3
2022-11-01 ET (fiscal 2022 q3)
2022 q2
2022-08-02 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-01-23 20:30 ET
IDEXX Laboratories to Release 2023 Fourth Quarter and Full Year Financial Results
2024-01-12 12:05 ET
IDEXX Expands Fecal Dx® Antigen Testing Platform with Cystoisospora Detection, Marking the Second Platform Expansion in Less than Two Years
2024-01-12 12:00 ET
IDEXX Announces Revolutionary Slide-Free Cellular Analyzer, IDEXX inVue Dx™ Transforming In-Clinic Workflows
2023-12-07 21:15 ET
IDEXX Laboratories Schedules Two Institutional Investor Events
2023-11-08 12:00 ET
IDEXX Expands SNAP Platform with Leish 4Dx Test to Support Veterinarians Globally in Diagnosing Vector-borne Diseases
2023-11-01 10:30 ET
IDEXX Laboratories Announces Third Quarter Results
2023-10-05 20:00 ET
IDEXX Laboratories to Release 2023 Third Quarter Financial Results
2023-08-01 10:30 ET
IDEXX Laboratories Announces Second Quarter Results
2023-07-25 11:00 ET
IDEXX Releases 2022 Corporate Responsibility Report, Providing Environmental, Social, and Governance Updates
2023-07-12 11:00 ET
IDEXX Laboratories Elects Irene Chang Britt to Board of Directors
2023-06-29 19:00 ET
IDEXX Laboratories to Release 2023 Second Quarter Financial Results
2023-06-15 11:00 ET
IDEXX Announces Novel Diagnostic Test for Kidney Injury, Expanding the Veterinary Industry's Most Comprehensive Renal Testing Portfolio
2023-05-10 13:15 ET
IDEXX Laboratories to Present at Stifel Conference and Announces 2023 Investor Day
2023-05-02 10:30 ET
IDEXX Laboratories Announces First Quarter Results
2023-04-13 19:00 ET
IDEXX Laboratories to Release 2023 First Quarter Financial Results
2023-02-21 21:05 ET
IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences
2023-02-20 12:00 ET
Groundbreaking IDEXX Study Reveals Opportunities to Increase Veterinary Practice Productivity
2023-02-06 11:30 ET
IDEXX Laboratories Announces Fourth Quarter and Full Year 2022 Results
2023-01-26 13:15 ET
IDEXX Laboratories to Release 2022 Fourth Quarter and Full Year Financial Results
2022-12-22 19:36 ET
IDEXX Laboratories to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
2022-11-01 10:30 ET
IDEXX Laboratories Announces Third Quarter Results
2022-10-11 19:15 ET
IDEXX Laboratories to Release 2022 Third Quarter Financial Results
2022-08-02 10:30 ET
IDEXX Laboratories Announces Second Quarter Results
2022-07-19 11:00 ET
IDEXX Announces New Goals in Its 2021 Corporate Responsibility Report and Advances Progress on Environmental, Social, and Governance Initiatives
2022-07-08 18:30 ET
IDEXX Laboratories to Release 2022 Second Quarter Financial Results
2022-06-21 11:00 ET
IDEXX Empowers Veterinarians with New Testing Insights that Support Earlier Diagnosis and Intervention for Preventive Care and Critical Cases
2022-05-18 18:30 ET
IDEXX Laboratories to Present at Stifel Conference and Announces 2022 Investor Day
2022-05-04 10:30 ET
IDEXX Laboratories Announces First Quarter Results
2022-04-11 19:00 ET
IDEXX Laboratories to Release 2022 First Quarter Financial Results
2022-02-17 20:00 ET
IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences
2022-02-02 11:30 ET
IDEXX Laboratories Announces Fourth Quarter and Full Year 2021 Results
2022-01-13 14:00 ET
PetDx and IDEXX Expand Access to OncoK9, the Cancer Liquid Biopsy Test for Dogs
2022-01-13 12:05 ET
IDEXX Innovative Diagnostic and Software Solutions Provide Workflow Efficiency and Faster, More Confident Clinical Decisions
2022-01-13 12:00 ET
IDEXX Enables Improved Cancer Diagnosis and Personalized Care through Expanded Oncology Offering
2022-01-11 20:15 ET
IDEXX Laboratories to Release 2021 Fourth Quarter and Full Year Financial Results
2021-11-02 10:30 ET
IDEXX Laboratories Announces Third Quarter Results
2021-10-08 20:15 ET
IDEXX Laboratories to Release 2021 Third Quarter Financial Results
2021-08-09 19:30 ET
IDEXX Laboratories to Host Virtual Investor Day
2021-07-30 10:30 ET
IDEXX Laboratories Announces Second Quarter Results
2021-06-30 20:05 ET
IDEXX Laboratories to Release 2021 Second Quarter Financial Results
2021-06-02 20:25 ET
IDEXX Acquires ezyVet
2021-05-26 15:45 ET
IDEXX Laboratories to Present at Stifel Conference and Announces 2021 Virtual Investor Day
2021-05-04 10:30 ET
IDEXX Laboratories Announces First Quarter Results
2021-04-08 17:30 ET
IDEXX Laboratories to Release 2021 First Quarter Financial Results
2021-02-16 21:30 ET
IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences
2021-02-02 11:30 ET
IDEXX Laboratories Announces Fourth Quarter and Full Year 2020 Results
2021-01-28 12:30 ET
­­IDEXX and the Tuskegee University College of Veterinary Medicine Announce Landmark Initiative
2021-01-11 19:00 ET
IDEXX Laboratories to Release 2020 Fourth Quarter and Full-Year Financial Results
2020-11-12 12:30 ET
IDEXX Laboratories Elects Dr. Asha S. Collins to Board of Directors
2020-10-29 10:30 ET
IDEXX Laboratories Announces Third Quarter Results
2020-10-05 20:15 ET
IDEXX Laboratories to Release 2020 Third Quarter Financial Results
2020-08-13 11:30 ET
IDEXX Laboratories Provides U.S. Companion Animal Market Trends Update
2020-08-12 11:32 ET
IDEXX expands ImageVue digital imaging portfolio, making enhanced radiation safety and superior diagnostic image quality affordable to more veterinarians
2020-08-12 11:30 ET
IDEXX launches groundbreaking new ProCyte One Hematology Analyzer with dramatically simplified user experience
2020-08-10 11:30 ET
IDEXX Laboratories to Host Virtual Investor Day
2020-07-31 10:30 ET
IDEXX Laboratories Announces Second Quarter Results
2020-07-20 17:00 ET
IDEXX Laboratories to Release 2020 Second Quarter Financial Results and Host Virtual Investor Day
2020-06-05 11:00 ET
OPTI Medical Systems Receives CE Mark for Its OPTI SARS-CoV-2 RNA PCR Test Kit for Detection of the Virus Causing COVID-19
2020-05-26 21:00 ET
IDEXX Laboratories Provides U.S. Companion Animal Market Trends Update
2020-05-18 17:30 ET
IDEXX Laboratories to Present at Stifel Conference
2020-05-07 11:30 ET
OPTI Medical Systems Receives US FDA Emergency Use Authorization for Its OPTI SARS-CoV-2 RNA PCR Test Kit for Detection of the Virus Causing COVID-19
2020-04-30 10:30 ET
IDEXX Laboratories Announces First Quarter Results
2020-04-20 11:30 ET
IDEXX Makes Pet Test for COVID-19 Virus Available to Veterinarians
2020-04-14 15:00 ET
IDEXX Laboratories to Release 2020 First Quarter Financial Results
2020-03-13 11:30 ET
Leading Veterinary Diagnostic Company Sees No COVID-19 Cases in Pets
2020-02-14 16:30 ET
IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences
2020-02-12 21:15 ET
IDEXX Laboratories Announces Increase in Share Repurchase Program Authorization
2020-01-31 11:30 ET
IDEXX Laboratories Announces Fourth Quarter and Full Year 2019 Results
2020-01-17 12:30 ET
Latest IDEXX Innovations Designed to Enhance Patient Care and Drive Veterinary Productivity
2020-01-17 12:30 ET
IDEXX Launches Rapid Digital Cytology Service to Further Accelerate Delivery of Veterinary Healthcare
2020-01-15 12:30 ET
IDEXX Laboratories Announces Senior Leadership Changes in Support of Global Companion Animal Group Growth
2020-01-10 16:30 ET
IDEXX Laboratories to Release 2019 Fourth Quarter and Full-Year Financial Results
2019-10-31 10:30 ET
IDEXX Laboratories Announces Third Quarter Results
2019-10-24 11:30 ET
IDEXX Laboratories Announces Leadership Changes
2019-10-10 17:30 ET
IDEXX Laboratories to Release 2019 Third Quarter Financial Results
2019-10-02 11:30 ET
IDEXX Breakthrough Kidney Function Test Now Key Component of IRIS Staging Guidelines
2019-08-06 18:00 ET
IDEXX Laboratories to Host 2019 Investor Day
2019-07-18 20:00 ET
IDEXX Laboratories Elects Sam Samad to Board of Directors
2019-07-15 18:00 ET
IDEXX Laboratories to Release 2019 Second Quarter Financial Results
2019-07-01 12:30 ET
IDEXX Laboratories Chairman, President and Chief Executive Officer, Jonathan Ayers, Taking Medical Leave of Absence
2019-04-23 10:00 ET
IDEXX CEO Establishes Wild Cat Conservation Foundation
2019-04-02 15:30 ET
IDEXX Laboratories to Release 2019 First Quarter Financial Results

SEC forms

Show financial reports only

SEC form 10
2024-02-22 00:00 ET
IDEXX Laboratories published news for 2023 q4
SEC form 8
2024-02-05 00:00 ET
IDEXX Laboratories published news for 2023 q4
SEC form 8
2024-02-05 00:00 ET
IDEXX Laboratories reported for 2023 q4
SEC form 10
2023-11-01 16:20 ET
IDEXX Laboratories published news for 2023 q3
SEC form 8
2023-11-01 06:30 ET
IDEXX Laboratories reported for 2023 q3
SEC form 10
2023-11-01 00:00 ET
IDEXX Laboratories published news for 2023 q3
SEC form 10
2023-08-01 16:08 ET
IDEXX Laboratories published news for 2023 q2
SEC form 6
2023-08-01 06:30 ET
IDEXX Laboratories reported for 2023 q2
SEC form 8
2023-08-01 00:00 ET
IDEXX Laboratories published news for 2023 q2
SEC form 10
2023-08-01 00:00 ET
IDEXX Laboratories published news for 2023 q2
SEC form 6
2023-07-12 17:00 ET
IDEXX Laboratories published news for 2023 q2
SEC form 6
2023-07-12 07:01 ET
IDEXX Laboratories published news for 2023 q2
SEC form 8
2023-05-02 00:00 ET
IDEXX Laboratories published news for 2023 q1
SEC form 10
2023-05-02 00:00 ET
IDEXX Laboratories published news for 2023 q1
SEC form 10
2023-02-16 17:08 ET
IDEXX Laboratories reported for 2022 q4
SEC form 10
2023-02-16 00:00 ET
IDEXX Laboratories reported for 2022 q4
SEC form 6
2023-02-06 06:31 ET
IDEXX Laboratories published news for 2022 q4
SEC form 8
2023-02-06 00:00 ET
IDEXX Laboratories published news for 2022 q4
SEC form 10
2022-11-01 16:33 ET
IDEXX Laboratories reported for 2022 q3
SEC form 6
2022-11-01 06:59 ET
IDEXX Laboratories published news for 2022 q3
SEC form 10
2022-11-01 00:00 ET
IDEXX Laboratories reported for 2022 q3
SEC form 8
2022-11-01 00:00 ET
IDEXX Laboratories published news for 2022 q3
SEC form 6
2022-10-21 16:36 ET
IDEXX Laboratories published news for 2022 q3
SEC form 10
2022-08-02 15:01 ET
IDEXX Laboratories reported for 2022 q2
SEC form 6
2022-08-02 06:31 ET
IDEXX Laboratories published news for 2022 q2
SEC form 10
2022-08-02 00:00 ET
IDEXX Laboratories reported for 2022 q2
SEC form 8
2022-08-02 00:00 ET
IDEXX Laboratories published news for 2022 q2
SEC form 6
2022-07-15 16:59 ET
IDEXX Laboratories published news for 2022 q2
SEC form 6
2022-06-14 16:30 ET
IDEXX Laboratories published news for 2022 q1
SEC form 6
2022-05-13 16:00 ET
IDEXX Laboratories published news for 2022 q1
SEC form 10
2022-05-04 14:57 ET
IDEXX Laboratories reported for 2022 q1
SEC form 6
2022-05-04 06:31 ET
IDEXX Laboratories published news for 2022 q1
SEC form 8
2022-05-04 00:00 ET
IDEXX Laboratories published news for 2022 q1
SEC form 10
2022-05-04 00:00 ET
IDEXX Laboratories reported for 2022 q1
SEC form 6
2022-03-31 16:01 ET
IDEXX Laboratories published news for 2021 q4
SEC form 6
2022-03-17 17:00 ET
IDEXX Laboratories published news for 2021 q4
SEC form 10
2022-02-16 14:57 ET
IDEXX Laboratories published news for 2021 q4
SEC form 10
2022-02-16 00:00 ET
IDEXX Laboratories published news for 2021 q4
SEC form 6
2022-02-02 06:30 ET
IDEXX Laboratories published news for 2021 q4
SEC form 8
2022-02-02 00:00 ET
IDEXX Laboratories published news for 2021 q4
SEC form 6
2021-12-09 16:15 ET
IDEXX Laboratories published news for 2021 q3
SEC form 10
2021-11-02 14:21 ET
IDEXX Laboratories published news for 2021 q3
SEC form 6
2021-11-02 06:33 ET
IDEXX Laboratories published news for 2021 q3
SEC form 10
2021-11-02 00:00 ET
IDEXX Laboratories published news for 2021 q3
SEC form 8
2021-11-02 00:00 ET
IDEXX Laboratories published news for 2021 q3
SEC form 6
2021-09-03 17:01 ET
IDEXX Laboratories published news for 2021 q2
SEC form 10
2021-07-30 14:48 ET
IDEXX Laboratories published news for 2021 q2
SEC form 6
2021-07-30 06:38 ET
IDEXX Laboratories published news for 2021 q2
SEC form 10
2021-07-30 00:00 ET
IDEXX Laboratories published news for 2021 q2
SEC form 8
2021-07-30 00:00 ET
IDEXX Laboratories published news for 2021 q2
SEC form 6
2021-05-18 17:01 ET
IDEXX Laboratories published news for 2021 q1
SEC form 10
2021-05-04 16:12 ET
IDEXX Laboratories published news for 2021 q1
SEC form 6
2021-05-04 06:30 ET
IDEXX Laboratories published news for 2021 q1
SEC form 10
2021-05-04 00:00 ET
IDEXX Laboratories published news for 2021 q1
SEC form 8
2021-05-04 00:00 ET
IDEXX Laboratories published news for 2021 q1
SEC form 6
2021-03-31 16:02 ET
IDEXX Laboratories published news for 2020 q4
SEC form 10
2021-02-12 15:22 ET
IDEXX Laboratories published news for 2020 q4
SEC form 6
2021-02-10 16:30 ET
IDEXX Laboratories published news for 2020 q4
SEC form 6
2021-02-02 06:31 ET
IDEXX Laboratories published news for 2020 q4
SEC form 6
2020-11-20 17:03 ET
IDEXX Laboratories published news for 2020 q3
SEC form 6
2020-11-12 07:31 ET
IDEXX Laboratories published news for 2020 q3
SEC form 6
2020-11-10 19:02 ET
IDEXX Laboratories published news for 2020 q3
SEC form 10
2020-10-29 15:43 ET
IDEXX Laboratories published news for 2020 q3
SEC form 6
2020-10-29 06:31 ET
IDEXX Laboratories published news for 2020 q3